Compare DXCM & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXCM | KVUE |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9B | 32.9B |
| IPO Year | 2005 | 2023 |
| Metric | DXCM | KVUE |
|---|---|---|
| Price | $73.37 | $19.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 11 |
| Target Price | ★ $85.33 | $19.45 |
| AVG Volume (30 Days) | 4.1M | ★ 16.6M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.82% |
| EPS Growth | ★ 47.18 | 40.74 |
| EPS | ★ 0.51 | 0.25 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $14.46 | $4.85 |
| Revenue Next Year | $12.31 | $2.63 |
| P/E Ratio | $140.27 | ★ $77.12 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.11 | $14.02 |
| 52 Week High | $82.36 | $22.44 |
| Indicator | DXCM | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 59.24 |
| Support Level | $62.02 | $16.83 |
| Resistance Level | $74.08 | $20.13 |
| Average True Range (ATR) | 2.63 | 0.39 |
| MACD | -0.36 | -0.04 |
| Stochastic Oscillator | 43.09 | 67.32 |
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.